Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis.
Cost-effectiveness
Flu
Health policy
Pain-free vaccines
Vaccine efficacy
Vaccine safety
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
03
06
2024
accepted:
02
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
Although vaccination is considered the most effective weapon against influenza, coverage rates, national vaccination policies, and funding vary largely around the globe. Despite their huge potential for achieving herd immunity, child-focused national vaccination strategies that favor pain-free nasal vaccines are uncommon. CENTRAL, Embase, and MEDLINE were last searched on November 13, 2023. Active-controlled randomized controlled trials comparing the live-attenuated intranasal vaccine with the inactivated intramuscular influenza vaccine in children were included. Event rates of laboratory-confirmed influenza virus infection, all-cause mortality, hospitalization, serious adverse events, adverse events, and financial outcomes were extracted based on the PRISMA 2020 Guideline. PROSPERO: CRD42021285412. Pooled odds ratios (ORs) with 95% confidence intervals (CI) were calculated using the random-effects model when at least three comparable outcomes were available. We found no significant difference between quadrivalent live-attenuated intranasal and trivalent inactivated intramuscular (OR = 1.48; 95% CI 0.49-4.45) or between trivalent live-attenuated intranasal and inactivated intramuscular vaccines (OR = 0.77, CI = 0.44-1.34) regarding their efficacy. However, the subgroup analysis of large, multi-center trials indicated that the trivalent live attenuated intranasal influenza vaccine was superior to the trivalent inactivated intramuscular influenza vaccine (12,154 people, OR = 0.50, CI = 0.28-0.88). Only 23 "vaccine-related serious adverse events" were recorded among 17 833 individuals, with no significant difference between methods. The widespread initiation of pediatric national flu vaccination programs prioritizing the live-attenuated intranasal influenza vaccine would be beneficial. Multi-continent, high-quality studies that include children younger than two years old and those living in subtropical and tropical regions are needed to further enhance our understanding.
Identifiants
pubmed: 39367499
doi: 10.1186/s12967-024-05676-9
pii: 10.1186/s12967-024-05676-9
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Comparative Study
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
903Informations de copyright
© 2024. The Author(s).
Références
Khaled M. Influenza (seasonal). 2024. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) . World Health Organization. Accessed 25 Apr 2024.
Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2023–2024. Pediatrics. 2023;152: e2023063773.
doi: 10.1542/peds.2023-063773
Young BE, Chen M. Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology. Hum Vaccin Immunother. 2020;16:1659–67.
pubmed: 32017650
pmcid: 7482764
doi: 10.1080/21645515.2019.1703455
Ilya K. Managing seasonal vaccination policies and coverage in the European region. 2014. https://www.who.int/europe/activities/managing-seasonal-vaccination-policies-and-coverage-in-the-european-region . WHO Task Force for Global Health. Accessed 16 Apr 2024.
Al Awaidi S, Abusrewil S, AbuHasan M, Akcay M, Aksakal FNB, Bashir U, Elahmer O, Esteghamati A, Gahwagi M, Mirza YK, et al. Influenza vaccination situation in Middle-East and North Africa countries. Report of the 7th MENA Influenza Stakeholders Network (MENA-ISN). J Infect Public Health. 2018;11:845–50.
pubmed: 30126699
pmcid: 7102733
doi: 10.1016/j.jiph.2018.07.003
Hirve S. Seasonal influenza vaccine use in low and middle income countries in the tropics and subtropics. A systematic review. Geneva: Department of pandemic and epidemic diseases, World Health Organization; 2015.
McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children <2 years of age: Examination of selected adverse events reported to the vaccine adverse event reporting system (VAERS) after thimerosal-free or thimerosal-containing vaccine. Vaccine. 2008;26:427–9.
pubmed: 18093701
doi: 10.1016/j.vaccine.2007.10.071
Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016;137: e20153279.
pubmed: 26738884
pmcid: 4732363
doi: 10.1542/peds.2015-3279
Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza vaccines: successes and continuing challenges. J Infect Dis. 2021;224:S405–19.
pubmed: 34590139
pmcid: 8482026
doi: 10.1093/infdis/jiab269
Jhaveri R. Live attenuated influenza vaccine: is past performance a guarantee of future results? Clin Ther. 2018;40:1246–54.
pubmed: 30093132
doi: 10.1016/j.clinthera.2018.07.003
Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother. 2017;13:1640–52.
pubmed: 28532276
pmcid: 5512791
doi: 10.1080/21645515.2017.1313375
European Medicines Agency ETF. Replacement of quadrivalent seasonal influenza vaccines with trivalent vaccines in the EU, Removal of antigens from B/Yamagata lineage. Amsterdam: European Medicines Agency; 2024. https://www.ema.europa.eu/en/documents/other/replacement-quadrivalent-seasonal-influenza-vaccines-trivalent-vaccines-eu_en.pdf Accessed 15 Apr 2024.
US food and drug administration. Use of trivalent influenza vaccines for the 2024–2025 U.S. Influenza season. 2024. https://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza-season . Accessed 28 Apr 2024.
World Health Organization. Recommendations announced for influenza vaccine composition for the 2024–2025 northern hemisphere influenza season. 2024. https://www.who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season . Accessed 28 Apr 2024.
European centre for disease prevention and control. Influenza: recommended vaccinations. 2023. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1 . Accessed 8 Dec 2023.
Nogareda F, Gharpure R, Contreras M, Velandia M, Lucia Pacis C, Elena Chevez A, Azziz-Baumgartner E, Salas D. Seasonal influenza vaccination in the Americas: progress and challenges during the COVID-19 pandemic. Vaccine. 2023;41:4554–60.
pubmed: 37328348
doi: 10.1016/j.vaccine.2023.06.024
Therapeutic Goods Administration, Australian Government, Department of Health and Aged Care. 2024 seasonal influenza vaccines, information for consumers and health professionals. 2024. https://www.tga.gov.au/resources/publication/publications/2024-seasonal-influenza-vaccines . Accessed 28 Apr 2024.
Li J, Zhang Y, Hang X, Liu L. Influenza and universal vaccine research in China. Viruses. 2022;15:116.
pubmed: 36680158
pmcid: 9861666
doi: 10.3390/v15010116
Goldman RD, McGregor S, Marneni SR, Katsuta T, Griffiths MA, Hall JE, Seiler M, Klein EJ, Cotanda CP, Gelernter R, et al. Willingness to vaccinate children against influenza after the Coronavirus disease 2019 pandemic. J Pediatr. 2021;228:87-93.e82.
pubmed: 32771480
doi: 10.1016/j.jpeds.2020.08.005
Harris E. FDA will evaluate first self-administered FluMist vaccine. JAMA. 2023;330:1945–1945.
pubmed: 37938864
De Gioia ER, Porqueddu A, Nebiaj O, Bianconi A, Conni A, Montalti M, Pandolfi P, Todeschini R, Fantini MP, Gori D. The role of needle fear in pediatric flu vaccine hesitancy. A cross-sectional study in Bologna metropolitan area. Vaccines (Basel). 2022;10:1388.
pubmed: 36146466
pmcid: 9506010
doi: 10.3390/vaccines10091388
Bambery B, Douglas T, Selgelid MJ, Maslen H, Giubilini A, Pollard AJ, Savulescu J. Influenza vaccination strategies should target children. Public Health Ethics. 2017;11:221–34.
pubmed: 30135702
pmcid: 6093440
doi: 10.1093/phe/phx021
Minozzi S, Lytras T, Gianola S, Gonzalez-Lorenzo M, Castellini G, Galli C, Cereda D, Bonovas S, Pariani E, Moja L. Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis. EClinicalMedicine. 2022;46: 101331.
pubmed: 35360146
pmcid: 8961170
doi: 10.1016/j.eclinm.2022.101331
Guo J, Chen X, Guo Y, Liu M, Li P, Tao Y, Liu Z, Yang Z, Zhan S, Sun F. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine. 2024;42:1883–91.
pubmed: 38423813
doi: 10.1016/j.vaccine.2024.02.059
World Health Organization. Global influenza strategy 2019–2030. Geneva: WHO; 2019. https://iris.who.int/bitstream/handle/10665/311184/9789241515320-eng.pdf?sequence=18 . Accessed 26 Apr 2024.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021. https://doi.org/10.1371/journal.pmed.1003583 .
doi: 10.1371/journal.pmed.1003583
pubmed: 33780438
pmcid: 8007028
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
pubmed: 27919275
pmcid: 5139140
doi: 10.1186/s13643-016-0384-4
Randomized controlled trial of FluMist vs. Flucelvax. 2019. https://clinicaltrialsgov/show/. Accessed 10 Jan 2022.
Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204:845–53.
pubmed: 21846636
pmcid: 3156924
doi: 10.1093/infdis/jir436
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD004879.pub5 .
doi: 10.1002/14651858.CD004879.pub5
pubmed: 29388197
pmcid: 6491184
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI J Natl Cancer Inst. 1959;22:719–48.
pubmed: 13655060
Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986;124:719–23.
pubmed: 3766505
doi: 10.1093/oxfordjournals.aje.a114447
Paule RC, Mandel J. Consensus values and weighting factors. J Res Natl Bur Stand. 1977;1982(87):377–85.
Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20:3875–89.
pubmed: 11782040
doi: 10.1002/sim.1009
Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with r: a hands-on guide. 1st ed. Boca Raton: Chapman & Hall/CRC Press; 2021.
doi: 10.1201/9781003107347
A randomized double-blind trial to assess the safety and realtive efficacy of CAIV-T against inactivated influenza vaccine in children 6–59 months of age. 2005. http://www.whoint/trialsearch/Trial2aspx?TrialID=EUCTR2004-000585-13-IT . Accessed 10 Jan 2022.
Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, Group C-TCES. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685–96.
pubmed: 17301299
doi: 10.1056/NEJMoa065368
Ilyushina NA, Haynes BC, Hoen AG, Khalenkov AM, Housman ML, Brown EP, Ackerman ME, Treanor JJ, Luke CJ, Subbarao K, Wright PF. Live attenuated and inactivated influenza vaccines in children. J Infect Dis. 2015;211:352–60.
pubmed: 25165161
doi: 10.1093/infdis/jiu458
Effect of age and prior immunity to response to seasonal influenza vaccines in children. 2010. https://clinicaltrials.gov/show/NCT01246999 . Accessed 10 Jan 2022.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.3. 2022. www.training.cochrane.org/handbook . Accessed 22 May 2022.
GRADE handbook for grading quality of evidence and strength of recommendations. 2013. The GRADE working group. www.guidelinedevelopment.org/handbook . Accessed 22 May 2022.
Nypaver C, Dehlinger C, Carter C. Influenza and influenza vaccine. A review. J Midwifery Womens Health. 2021;66:45–53.
pubmed: 33522695
pmcid: 8014756
doi: 10.1111/jmwh.13203
Matrajt L, Halloran ME, Antia R. Successes and failures of the live-attenuated influenza vaccine: can we do better? Clin Infect Dis. 2019;70:1029–37.
pmcid: 7319054
doi: 10.1093/cid/ciz358
Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother. 2018;14:571–8.
pubmed: 28933664
pmcid: 5861782
doi: 10.1080/21645515.2017.1377376
Randomized study of immune response to licensed influenza vaccines in children and adolescents. 2014. https://clinicaltrials.gov/show/NCT02250274 . Accessed 10 Jan 2022.
Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Oymar K, Garcia ML, Krygier A, Costa H, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860–9.
pubmed: 17006278
doi: 10.1097/01.inf.0000237797.14283.cf
Safety of LAIV4 in children with asthma. 2018. https://clinicaltrials.gov/show/NCT03600428 . Accessed 10 Jan 2022.
Study of live, attenuated influenza vaccination in preterm and full-term infants. 2010. https://clinicaltrials.gov/show/NCT01194297 . Accessed 10 Jan 2022.
Sokolow AG, Stallings AP, Kercsmar C, Harrington T, Jimenez-Truque N, Zhu Y, Sokolow K, Moody MA, Schlaudecker EP, Walter EB, et al. Safety of live attenuated influenza vaccine in children with asthma. Pediatrics. 2022;149: e2021055432.
pubmed: 35342923
doi: 10.1542/peds.2021-055432
Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine. 2008;26:2841–8.
pubmed: 18462851
doi: 10.1016/j.vaccine.2008.03.046
Tarride JE, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon Outcomes Res. 2012;4:287–98.
pubmed: 23055756
pmcid: 3468276
doi: 10.2147/CEOR.S33444
Smolen LJ, Klein TM, Bly CA, Ryan KJ. Cost-effectiveness of live attenuated versus inactivated influenza vaccine among children. Am J Pharm Benefits. 2014;6:171–82.
Krishnan A, Dar L, Saha S, Narayan VV, Kumar R, Kumar R, Amarchand R, Dhakad S, Chokker R, Choudekar A, et al. Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: a 2-year, randomized, triple-blind, placebo-controlled trial. PLoS Med. 2021;18: e1003609.
pubmed: 33914729
pmcid: 8118535
doi: 10.1371/journal.pmed.1003609
Loeb M, Russell ML, Manning V, Fonseca K, Earn DJ, Horsman G, Chokani K, Vooght M, Babiuk L, Schwartz L, et al. Live attenuated versus inactivated influenza vaccine in hutterite children: a cluster randomized blinded trial. Ann Intern Med. 2016;165:617–24.
pubmed: 27538259
doi: 10.7326/M16-0513
Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, Trebbien R, Watson C, Findlay B, Pozo F, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28:2300116.
pubmed: 37227299
pmcid: 10283457
doi: 10.2807/1560-7917.ES.2023.28.21.2300116
Huang C, Fu X, Zhou Y, Mi F, Tian G, Liu X, Wu J, Ding C, Yan D, Li L, Yang S. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine. 2020;38:1332–44.
pubmed: 31948819
doi: 10.1016/j.vaccine.2019.11.071
Miller ER, Moro PL, Cano M, Shimabukuro TT. Deaths following vaccination: what does the evidence show? Vaccine. 2015;33:3288–92.
pubmed: 26004568
pmcid: 4599698
doi: 10.1016/j.vaccine.2015.05.023
Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kuhr J, Bujnowski T, Desgrandchamps D, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870–9.
pubmed: 17006279
doi: 10.1097/01.inf.0000237829.66310.85
Bandell A, Ambrose CS, Maniaci J, Wojtczak H. Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis. Expert Rev Vaccines. 2021;20:717–28.
pubmed: 33939928
doi: 10.1080/14760584.2021.1925113
Boddington NL, Mangtani P, Zhao H, Verlander NQ, Ellis J, Andrews N, Pebody RG. Live-attenuated influenza vaccine effectiveness against hospitalization in children aged 2–6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14–2015/16. Influenza Other Respir Viruses. 2022;16:897–905.
pubmed: 35531630
pmcid: 9343328
doi: 10.1111/irv.12990
Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head comparative studies: challenges and opportunities? J Crohns Colitis. 2016;11:S567–75.
Streiner DL. Alternatives to placebo-controlled trials. Can J Neurol Sci. 2007;34(Suppl 1):S37-41.
pubmed: 17469680
doi: 10.1017/S0317167100005540
Sackett DLSS, Richardson WS. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone; 2000.
Ainslie KEC, Haber M, Orenstein WA. Challenges in estimating influenza vaccine effectiveness. Expert Rev Vaccines. 2019;18:615–28.
pubmed: 31116070
pmcid: 6594904
doi: 10.1080/14760584.2019.1622419
Ainslie KEC, Riley S. Is annual vaccination best? A modelling study of influenza vaccination strategies in children. Vaccine. 2022;40:2940–8.
pubmed: 35410816
doi: 10.1016/j.vaccine.2022.03.065
Shi X, Li KQ, Mukherjee B. Current challenges with the use of test-negative designs for modeling COVID-19 vaccination and outcomes. Am J Epidemiol. 2023;192:328–33.
pubmed: 36446573
doi: 10.1093/aje/kwac203
Pearson CAB, Edmunds WJ, Hladish TJ, Eggo RM. Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo. Int J Epidemiol. 2022;51:265–78.
pubmed: 34458913
doi: 10.1093/ije/dyab172
Saldanha IJ, Skelly AC, Ley KV, Wang Z, Berliner E, Bass EB, Devine B, Hammarlund N, Adam GP, Duan-Porter D, et al. AHRQ methods for effective health care. In: Saldanha IJ, editor., et al., Inclusion of nonrandomized studies of interventions in systematic reviews of intervention effectiveness: an update. Rockville: Agency for Healthcare Research and Quality; 2022.
doi: 10.23970/AHRQEPCMETHODSGUIDENRSI
Wen F, Guo J, Huang S. A meta-analysis identified genes responsible for distinct immune responses to trivalent inactivated and live attenuated influenza vaccines. J Cell Physiol. 2019;234:5196–202.
pubmed: 30203415
doi: 10.1002/jcp.27327
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018;2:Cd004879.
pubmed: 29388195
Rosenthal NE, Carpenter CJ, James SP, Parry BL, Rogers SL, Wehr TA. Seasonal affective disorder in children and adolescents. Am J Psychiatry. 1986;143:356–8.
pubmed: 3953872
doi: 10.1176/ajp.143.3.356
Schrijver TV, Brand PL, Bekhof J. Seasonal variation of diseases in children: a 6-year prospective cohort study in a general hospital. Eur J Pediatr. 2016;175:457–64.
pubmed: 26494134
doi: 10.1007/s00431-015-2653-y
Sterne JACSJ, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
Hegyi P, Erőss B, Izbéki F, Párniczky A, Szentesi A. Accelerating the translational medicine cycle: the Academia Europaea pilot. Nat Med. 2021;27:1317–9.
pubmed: 34312557
doi: 10.1038/s41591-021-01458-8
Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245–51.
pubmed: 33965796
doi: 10.1016/j.puhe.2021.02.025
Alonso WJ, Yu C, Viboud C, Richard SA, Schuck-Paim C, Simonsen L, Mello WA, Miller MA. A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation. Sci Rep. 2015;5:17214.
pubmed: 26621769
pmcid: 4664865
doi: 10.1038/srep17214
Koul PA, Koul HP. Redefining the influenza equator. Lancet Glob Health. 2022;10: e1388.
pubmed: 36113521
doi: 10.1016/S2214-109X(22)00364-3
Gács Z, Koltai J. Understanding parental attitudes toward vaccination: comparative assessment of a new tool and its trial on a representative sample in Hungary. Vaccines. 2006;2022:10.
Taddio A, Chambers CT, Halperin SA, Ipp M, Lockett D, Rieder MJ, Shah V. Inadequate pain management during routine childhood immunizations: the nerve of it. Clin Ther. 2009;31(Suppl 2):S152-167.
pubmed: 19781434
doi: 10.1016/j.clinthera.2009.07.022
Chan KS-K, Wong CH-L, Choi HCW. Cost-effectiveness of intranasal live-attenuated influenza vaccine for children: a systematic review. Vaccines. 2022;10:1466.
pubmed: 36146544
pmcid: 9505322
doi: 10.3390/vaccines10091466
Wang Q, Jin H, Yang L, Jin H, Lin L. Cost-effectiveness of seasonal influenza vaccination of children in China: a modeling analysis. Infect Dis Poverty. 2023;12:92.
pubmed: 37821942
pmcid: 10566174
doi: 10.1186/s40249-023-01144-6
Kiseleva I. Current opinion in LAIV: a matter of parent virus choice. Int J Mol Sci. 2022;23:6815.
pubmed: 35743258
pmcid: 9224562
doi: 10.3390/ijms23126815
Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis. 2011;204:1475–82.
pubmed: 21949042
doi: 10.1093/infdis/jir561
Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, Hamid JS, Feinberg Y, Winter AL, Gubbay JB, et al. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial. Vaccine. 2015;33:535–41.
pubmed: 25488331
doi: 10.1016/j.vaccine.2014.11.044
Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R, Kemble G, Allende M, Hultquist M, Yi T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210–7.
pubmed: 18597900
pmcid: 2615200
doi: 10.1016/j.vaccine.2008.05.054
Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733–40.
pubmed: 11734733
doi: 10.1097/00006454-200108000-00004
A phase 2 study to evaluate immune responses of FluMist